Carregant...
Mechanisms of resistance to KRAS(G12C)-targeted therapy
KRAS mutations are among the most common drivers of human carcinogenesis, and are associated with poor prognosis and an aggressive disease course. With the advent of KRAS(G12C) inhibitors, the RAS protein is now targetable, with such inhibitors showing marked clinical responses across multiple tumor...
Guardat en:
| Publicat a: | Cancer Discov |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8178176/ https://ncbi.nlm.nih.gov/pubmed/33820777 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-20-1616 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|